DxTerity Earns SOC 2 Type 2 Compliance, Reinforcing Commitment to Secure Healthcare Data. Read more
  {modal url="index.php?option=com_content&view=category&layout=blog&id=18&Itemid=125" class="modalsign"}{/modal}
Type I Interferon (IFN-1) Talks and Poster Sessions
Anifrolumab Treatment May Particularly Benefit IFN-1 High Lupus Patients

White Paper

Two new lupus therapies target the influential IFN-1 pathway

To learn more about IFN-1 targeted therapies, download our white paper
img white paper 2 thumbnail

Better health management begins
at home

Subscribe to receive the latest information on new developments and products at DxTerity.